These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 35665368)

  • 1. Pathogenesis and treatment of multiple myeloma.
    Yang P; Qu Y; Wang M; Chu B; Chen W; Zheng Y; Niu T; Qian Z
    MedComm (2020); 2022 Jun; 3(2):e146. PubMed ID: 35665368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
    Heider M; Nickel K; Högner M; Bassermann F
    Oncol Res Treat; 2021; 44(12):672-681. PubMed ID: 34749378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy.
    Yang M; Chen Y; Zhu L; You L; Tong H; Meng H; Sheng J; Jin J
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotherapeutics for multiple myeloma.
    Zheleznyak A; Shokeen M; Achilefu S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Nov; 10(6):e1526. PubMed ID: 29701006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multiple myeloma: update on pathophysiology and management].
    Hanamura I; Iida S
    Rinsho Ketsueki; 2018; 59(5):529-538. PubMed ID: 29877243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Myeloma: New Insights and Therapeutic Approaches.
    Anderson KC; Kyle RA; Dalton WS; Landowski T; Shain K; Jove R; Hazlehurst L; Berenson J
    Hematology Am Soc Hematol Educ Program; 2000; ():147-165. PubMed ID: 11701540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.
    Castella M; Fernández de Larrea C; Martín-Antonio B
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30445802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic strategies for multiple myeloma.
    Mimura N; Hideshima T; Anderson KC
    Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies.
    Larsen JT; Kumar S
    Rare Cancers Ther; 2015; 3(1):47-68. PubMed ID: 27182478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
    Varga C; Laubach JP; Anderson KC; Richardson PG
    Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
    Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
    San Miguel J
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
    Chen T; Moscvin M; Bianchi G
    Front Oncol; 2020; 10():608815. PubMed ID: 33251153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.
    Abduh MS
    Saudi J Biol Sci; 2024 Feb; 31(2):103920. PubMed ID: 38283805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T cell therapies for multiple myeloma.
    Wu C; Zhang L; Brockman QR; Zhan F; Chen L
    J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.